Literature DB >> 4329953

Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy.

R L Stolfi, D S Martin, R A Fugmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4329953

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

1.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.

Authors:  D S Martin; R L Stolfi; R C Sawyer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation.

Authors:  S Spiegelman; R Sawyer; R Nayak; E Ritzi; R Stolfi; D Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

3.  Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.

Authors:  J W Darnowski; R C Sawyer; R L Stolfi; D S Martin; C A Lau-Cam
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Effect of uridine diphosphoglucose on levels of 5-phosphoribosyl pyrophosphate and uridine triphosphate in murine tissues.

Authors:  J R Colofiore; R C Sawyer; M E Balis; D S Martin
Journal:  Pharm Res       Date:  1989-10       Impact factor: 4.200

5.  Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System.

Authors:  R C Sawyer; R L Stolfi; S Spiegelman; D S Martin
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.